BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31072612)

  • 1. A Prospective Cohort Study to Define the Clinical Features and Outcome of Lung Cancers Harboring HER2 Aberration in Japan (HER2-CS STUDY).
    Ninomiya K; Hata T; Yoshioka H; Ohashi K; Bessho A; Hosokawa S; Ishikawa N; Yamasaki M; Shibayama T; Aoe K; Kozuki T; Harita S; Ueda Y; Murakami T; Fujimoto N; Yanai H; Toyooka S; Takata M; Hotta K; Kiura K;
    Chest; 2019 Aug; 156(2):357-366. PubMed ID: 31072612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
    Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
    Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic and Molecular Characteristics of HER2 (ERBB2)-Altered Non-Small Cell Lung Cancer: Implications for Precision Medicine.
    Lee Y; Lee B; Choi YL; Kang DW; Han J
    Mod Pathol; 2024 Jun; 37(6):100490. PubMed ID: 38588887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis.
    Ohashi K; Ninomiya K; Yoshioka H; Bessho A; Shibayama T; Aoe K; Ishikawa N; Kozuki T; Kawai H; Kuyama S; Miyoshi S; Fujitaka K; Obata H; Tsubata Y; Awaya Y; Inoue M; Inoue K; Horita N; Yanai H; Hotta K; Kiura K
    Lung Cancer; 2020 Dec; 150():83-89. PubMed ID: 33096420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
    Ahn BC; Han YJ; Kim HR; Hong MH; Cho BC; Lim SM
    Cancer Res Treat; 2023 Apr; 55(2):488-497. PubMed ID: 36397236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER2 mutations in Chinese patients with non-small cell lung cancer.
    Song Z; Yu X; Shi Z; Zhao J; Zhang Y
    Oncotarget; 2016 Nov; 7(47):78152-78158. PubMed ID: 27825109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
    Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
    Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
    Bai H; Mao L; Wang HS; Zhao J; Yang L; An TT; Wang X; Duan CJ; Wu NM; Guo ZQ; Liu YX; Liu HN; Wang YY; Wang J
    J Clin Oncol; 2009 Jun; 27(16):2653-9. PubMed ID: 19414683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.